Cost Effectiveness of Tofacitinib as Second Line Treatment Vs Using Biological Therapies In The Treatment of Moderate Rheumatoid Arthritis After Failure of Dmards In Guatemala In 2014
May 1, 2015, 00:00
10.1016/j.jval.2015.03.943
https://www.valueinhealthjournal.com/article/S1098-3015(15)01000-1/fulltext
Title :
Cost Effectiveness of Tofacitinib as Second Line Treatment Vs Using Biological Therapies In The Treatment of Moderate Rheumatoid Arthritis After Failure of Dmards In Guatemala In 2014
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01000-1&doi=10.1016/j.jval.2015.03.943
First page :
A163
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
390